SBRT for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. The primary purpose of this study is to determine the feasibility and safety of two fraction SBRT in patients with localized prostate cancer.
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, androgen-deprivation therapy (ADT) is left to the discretion of the treating radiation oncologist, so you may want to discuss your current medications with them.
Is SBRT safe for treating prostate cancer?
How is the Two-Fraction Stereotactic Body Radiation Therapy (SBRT) treatment for prostate cancer different from other treatments?
Two-Fraction Stereotactic Body Radiation Therapy (SBRT) for prostate cancer is unique because it delivers a high dose of radiation in just a few sessions, which may be more effective due to the specific characteristics of prostate cancer cells. This approach, often using the CyberKnife system, can offer better precision and potentially improved outcomes compared to traditional radiation therapies that use lower doses over more sessions.35678
What data supports the effectiveness of the treatment Two-Fraction Stereotactic Body Radiation Therapy (SBRT) for prostate cancer?
Who Is on the Research Team?
Jonathan Lischalk
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
This trial is for men over 18 with localized prostate cancer, staged TX-T2c. They must have a prostate size under 60cc, no prior malignancies within the last 5 years, and agree to use effective contraception. Excluded are those with evidence of more advanced cancer spread, large prostates over 60cc, recent prostate surgeries or treatments affecting the pelvis.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with a simultaneous integrated boost (SIB) for localized prostate cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Two-Fraction Stereotactic Body Radiation Therapy (SBRT)
Two-Fraction Stereotactic Body Radiation Therapy (SBRT) is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor